CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
Repetitive transcranial magnetic stimulationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05480410
NCT05480410N/ACompleted

Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) on Pain and Quality of Life in Patients With Cancer Neuropathic Pain. Clinical Trial

Fundacion Universitaria Maria Cano·interventional·Posted Jul 29, 2022·Updated Jun 6, 2025

In Brief

A clinical study evaluating Repetitive transcranial magnetic stimulation for Neuropathic Pain. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effectiveness of Repetitive transcranial magnetic stimulation (rTMS) on pain and quality of life in patients with cancer neuropathic pain. Although there are currently different therapeutic options for neuropathic pain, most are limited or restricted to pharmacotherapy. Transcranial magnetic stimulation (TMS) is a tool recently incorporated into neuroscience in the management of neuropathic cancer pain. The study will include 10 patients with oncologic neuropathic pain who will receive 20 sessions of rTMS and the effect on pain and quality of life.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesColombia
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedJul 29, 2022
Enrollment StartJun 11, 2022
Primary CompletionJan 30, 2023
Study CompletionFeb 23, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.9 years ago

Interventions

Repetitive transcranial magnetic stimulationdevice

rTMS is a minimal invasive technique which focus on the M1 cortex. It can stimulate the cortex by depolarizing superficial neurons. For this study we will use a MagVenture MagPro R20